Navigation Links
Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
Date:11/2/2010

ts';s.linkTrackEvents='event12';s.prop5='share it release';s.eVar3=s.prop5; s.prop15='106500673';s.prop16='CrowdFactory_'+socialText;s.prop5+='_'+s.prop16;s.prop49=s.pageName;s.events='event12';s.tl(this,'o','CrowdFactory_'+socialText); }); });  

CARMIEL, Israel, Nov. 2, 2010 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE: PLX), announced today positive preliminary data from the first 15 patients that completed the Company's nine month, worldwide, multi-center, open-label, switchover trial of taliglucerase alfa for the treatment of Gaucher disease under a protocol cleared by the U.S. Food and Drug Administration (FDA).  The data indicate that patients can safely be switched to taliglucerase alfa from imiglucerase (Cerezyme®).  

Patients enrolled in the trial were switched from imiglucerase (doses ranging from 10-60 U/kg every other week) to an equivalent dose using the same number of units of taliglucerase alfa.  The data from the first 15 patients demonstrate that maintenance of efficacy was achieved over a nine month period with no increased safety concerns.  Patients' hemoglobin and platelet counts remained stable demonstrating hematological stability.  As measured by MRI, mean spleen volume and liver volume also remained stable.  There was no evidence of increased safety concerns in patients switched from Cerezyme® to taliglucerase alfa and there were no drug related serious adverse events.  Hypersensitivity reactions were not reported in this patient group.  One patient developed non-neutralizing IgG antibodies to taliglucerase at the end of the study.  Detailed data will be presented at an upcoming medical meeting.

The switchover trial was originally designed and cleared by FDA to enroll 15 patients, however, it was expanded to recruit a total of 30 patients as a result of the shortage of enzyme replacement therapy for Gaucher patients. 
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
2. Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs
3. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
4. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
5. Talecris Biotherapeutics Receives FDA Approval for Gamunex®-C
6. Talecris Biotherapeutics to Report Third Quarter 2010 Financial Results
7. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
8. Garnet BioTherapeutics Announces First Patient Treated in Trial of New Therapy for Improvement in Scar Appearance
9. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
10. Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing
11. Oxygen Biotherapeutics, Inc. Expands Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 Nuclear medicine ... 2015. Radiopharmaceuticals/ Nuclear are drugs that ... imaging field to diagnose and treat diseases. ... Increasing awareness for radiopharmaceuticals, and ready availability of ... market. Furthermore, increased public awareness and use of ...
(Date:9/23/2014)... 23, 2014 FDNA ... d,une série de démonstrations personnelles   ... domaine de l,analyse de la dysmorphologie assistée ... n° 1035 lors de la réunion ASHG 2014, qui ... , en Californie. FDNA présentera la ...
(Date:9/23/2014)... Dans les secteurs ... ferroviaire ou encore l,énergie, les machines, de ... à leurs données. Ces données de masse ... cœur des voitures, trains, avions, appareils médicaux… ... le nombre de machines connectées d,ici 2020. ...
Breaking Medicine Technology:Global Nuclear Medicine Market - Growth, Trends & Forecasts (2014-2019) 2FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à l'ASHG 2014 2FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à l'ASHG 2014 3Altran transforme le big data du monde industriel en nouveau business 2
... ThermalTherapeutic Systems, Inc. (TTS), maker of portable ... F.H. Smith as President and Chief Executive Officer. Mr. ... operational executive in the high-tech sector, focused on biotech, ... F. Vennare will transition to the role of Executive ...
... 2011 Bay Sleep, the West Coast,s largest and ... its newest, state-of-the-art sleep clinic in Oakland, California.  Located ... Sleep,s 16th clinic open for business. Services include sleep ... dispensing CPAP and other therapies for patients diagnosed with ...
Cached Medicine Technology:ThermalTherapeutic Systems, Inc. Names Gardiner F. H. Smith, President and Chief Executive Officer 2Bay Sleep Clinic Continues Growth in California and Beyond 2
(Date:9/23/2014)... 23, 2014 Grinnell Mutual seeks ... projects in the Midwest. Working Together Making It ... non-profit organizations with projects positively impacting their communities. ... marketplace make their communities a better places,” said ... Community Relations Barb Baker. “Their leadership—as coaches, as ...
(Date:9/23/2014)... News) -- The number of ,rogue, wholesale distributors ... so doctors need to be vigilant when purchasing ... Tuesday. In a statement, the agency said ... launched a program to educate doctors and other ... purchasing procedures. The program aims to protect patients ...
(Date:9/23/2014)... A national report showing the benefits of ... for providing Medicaid services was released today by ... report, "Why Congress Must Save the Medicaid Primary ... to Ensure Access to Life-Saving Primary Care Will ... Medicaid patients, access to internists and pediatricians (and ...
(Date:9/23/2014)... September 23, 2014 Trevera provides ... market. Included are Oracle Managed Services , ... supports all versions of Oracle E-Business Databases ... , Trevera has announced a significant enhancement ... need help with their software technology management, project ...
(Date:9/23/2014)... 2014 SOURCE: Solutions from Our ... were made to Rimidi Diabetes and ... with business solutions to challenges faced by patients and ... collaboration between The Hitachi Foundation, Village ... entrepreneurs with the investment capital, mentoring, and support needed ...
Breaking Medicine News(10 mins):Health News:Grinnell Mutual Invites Submissions for Innovative, Collaborative Local Projects in Its Second Annual Working Together Making It Better Promotion 2Health News:Unless Congress acts, patients may soon lose access to primary care 2Health News:Unless Congress acts, patients may soon lose access to primary care 3Health News:Trevera, Inc adds Management Support to Services 2Health News:Trevera, Inc adds Management Support to Services 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 2Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 4Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 5
... CHICAGO For years, it was believed that obese women ... body fat actually protected against bone loss. However, a study ... of North America (RSNA) found that having too much internal ... bone health. "We know that obesity is a major ...
... , CAMBRIDGE, Mass. (November 29, 2010) Whitehead Institute ... the microRNA 125b (miR-125b) can independently cause leukemia and ... this week,s online edition of the Proceedings of the ... in many cancers, but in humans and mice, can ...
... With the emergence of an epidemic of obesity and type ... habits that may affect the risk of metabolic diseases is ... drinkers tend to have about 30% lower risk of developing ... tend to be at lower risk of developing metabolic ...
... Goodwin HealthDay Reporter , MONDAY, Nov. 29 (HealthDay ... teens over the last few decades, with some of the ... a new report. In one startling statistic cited in ... and Quality found that hospitalizations for eating disorders jumped by ...
... iridescence of a butterfly,s wing, investigators at the University ... and Applied Sciences have developed a color-changing patch that ... indicate the strength of exposure to blasts from explosives ... color change to the intensity of exposure to provide ...
... , MONDAY, Nov. 29 (HealthDay News) -- Children and teens ... triclosan may be at increased risk for hay fever and ... can actually make people sick, researchers say. The study ... bisphenol A (BPA) may weaken an adult,s immune system. ...
Cached Medicine News:Health News:Belly fat puts women at risk for osteoporosis 2Health News:Tiny RNA shown to cause multiple types of leukemia 2Health News:Tiny RNA shown to cause multiple types of leukemia 3Health News:Moderate alcohol consumption lowers the risk of metabolic diseases 2Health News:Rate of Eating Disorders in Kids Keeps Rising 2Health News:Rate of Eating Disorders in Kids Keeps Rising 3Health News:Color-changing 'blast badge' detects exposure to explosive shock waves 2Health News:Too Much Hygiene May Affect Immune System, Study Suggests 2
The Bledsoe Flatform Boot is designed with a flat innersole for procedures where toe dorsiflexion is not permissible....
The Bledsoe Achilles Boot saves time by eliminating casting series required to stretch the achilles tendon during rehab....
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... Bauerfeind™ AchilloTrain® The viscoelastic insert runs ... application of pressure and targeted intermittent ... reduction of painful irritation of the ... integrated viscoelastic heel wedge (raises heel ...
Medicine Products: